Azilsartan medoxomil - chlorthalidone

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Essential Hypertension

Drug Information

Target Indication

Essential Hypertension

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA12/7/2011

Edarbi

Edarbi is indicated for the treatment of essential hypertension in adults.

EMA12/7/2011

Ipreziv

Ipreziv is indicated for the treatment of essential hypertension in adults.

Drug Science

Mechanism of action & safety profile

Developer

TAK

TAKEDA PHARMACEUTICAL CO LTD

Related Pipeline

Fabry Disease

Primary Immunodeficiency Disease

Type 2 Diabetes Mellitus

Primary Immunodeficiency Diseases (PID)

Myelodysplastic Syndrome